Both NVIDIA (NASDAQ:NVDA) and AstraZeneca (NYSE:AZN) have gained over 10% in price in the past week. NVIDIA was up due to a positive earnings beat with growth in artificial intellegence. AstraZeneca saw progress on the drug Imfinzi which is set to battle lung cancer, among other potential growth in drug pipeline research. Investors should be excited as both companies continue to execute going forward.
On June 21, 2017, an Ethereum “flash crash” sent cryptocurrency owners into a full-fledged panic. The Ethereum price crashed to a low of $0.10 from $319 on the GDAX cryptocurrency exchange. Shortly after the event, GDAX Vice President Adam White wrote in a June 21 blog post that there were no indications of wrongdoing.
The temporary crash, which reportedly took place in a....More>>>
Too often, consumers surrender to overly high cable and Internet bills just to avoid the hassle of trying to land a better rate. I recently set out on a mission to trim my bill. By picking up the phone, waiting on hold for hours at a time and politely exercising patience when dealing with customer service reps, the extra effort was well worth it in the end.....More>>>
The S&P 500 is up almost 14% since Trump’s election as President. That’s certainly on the high side of historical runs for the stock market over a short period of time, but not unprecedented. For example, it falls in the top 10% of 4 month returns for the market looking back over US history. However, Trump and his policies have less to do with this move than appearances might....More>>>
Chicago, IL, based Investment company Ctc Llc buys Amazon.com, sells PowerShares QQQ Trust Series 1, SPDR Gold Trust, iShares MSCI Brazil Capped Index Fund during the 3-months ended 2017-03-31, according to the most recent filings of the investment company, Ctc Llc. As of 2017-03-31, Ctc Llc owns 4 stocks with a total value of $98 million. These are the details of the buys and sells.
Oil and gas majors like ExxonMobil Corporation (NYSE:XOM) and Royal Dutch Shell Plc (NYSE:RDS-B) have had a rough run since mid-2014. But these two industry giants are making the changes needed to deal with today’s difficult energy markets, just like they’ve done time and time before. You could worry, but you really don’t need to. Here are their bonafides.
Shares of Achaogen (AKAO) rose by up to 90% just a few months after my December article suggesting readers buy the secondary offering. The stock has completed the round trip back down and then some, currently in the red by 20% from where we first started.